The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties
Open accessAbstract
The interplay among commonly used physicochemical properties in drug design was examined and utilized to create a prospective design tool focused on the alignment of key druglike attributes. Using a set of six physicochemical parameters ((a) lipophilicity, calculated partition coefficient (ClogP); (b) calculated distribution coefficient at pH = 7.4 (ClogD); (c) molecular weight (MW); (d) topological polar surface area (TPSA); (e) number of hydrogen bond donors (HBD); (f) most basic center (pK(a))), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compounds (N = 11 303). The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0-6), in comparison to 60% of the Pfizer CNS candidates. This analysis suggests that this algorithm could potentially be used to identify compounds with a higher probability of successfully testing hypotheses in the clinic. In addition, a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set. The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure-activity relationships (SAR) by expanding medicinal chemistry design space through a holistic assessment approach. Based on six physicochemical properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compounds with increased probability of success.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Research works printed but not linked: 21
- Abad-Zapatero C., 2007, Expert Opin. Drug Discovery, 2, 469, 10.1517/17460441.2.4.469 · DOI · Paper page
- Keserue G. M., 2009, Nat. Rev. Drug Discovery, 8, 203, 10.1038/nrd2796 · DOI · Paper page
- Kalgutkar A. S., 2008, Biotechnol.: Pharm. Aspects, 9, 27
- Kalgutkar A. S., 2005, Curr. Drug Metab., 6, 161, 10.2174/1389200054021799 · DOI · Paper page
- Kalgutkar A. S., 2005, Expert Opin. Drug Metab. Toxicol., 1, 91, 10.1517/17425255.1.1.91 · DOI · Paper page
- 10.1021/cn100007x · DOI · Paper page
- Ertl P., 2000, J. Med. Chem., 43, 3714, 10.1021/jm000942e · DOI · Paper page
- Feng B., 2008, Drug Metab. Dispos., 36, 268, 10.1124/dmd.107.017434 · DOI · Paper page
- Hosea N. A., 2009, J. Clin. Pharmacol., 49, 513, 10.1177/0091270009333209 · DOI · Paper page
- Gao H., 2008, Drug Metab. Dispos., 36, 2130, 10.1124/dmd.107.020131 · DOI
- Hughes J. D., 2008, Bioorg. Med. Chem. Lett., 18, 4872, 10.1016/j.bmcl.2008.07.071 · DOI · Paper page
- Lipinski C. A., 2004, Drug Discovery Today: Technol., 1, 337, 10.1016/j.ddtec.2004.11.007 · DOI · Paper page
- Waterhouse Rikki N., 2003, Mol. Imaging Biol., 5, 376, 10.1016/j.mibio.2003.09.014 · DOI · Paper page
- E. C. Harrington J., 1965, Ind. Qual. Control, 21, 494
- Le Bailly de Tilleghem C., 2005, J. Chem. Inf. Model., 45, 758, 10.1021/ci049787t · doi:10.1021/ci049787t
- Mandal A., 2007, J. Chem. Inf. Model., 47, 981, 10.1021/ci600556v · doi:10.1021/ci600556v
- Gehlhaar D. K., 1995, Chem. Biol., 2, 317, 10.1016/1074-5521(95)90050-0 · DOI · Paper page
- Deacon M., 2007, J. Pharmacol. Toxicol. Methods, 55, 238, 10.1016/j.vascn.2006.09.003 · doi:10.1016/j.vascn.2006.09.003
- Lowe C. W., 1967, Trans. Inst. Chem. Eng., 45, T3
- Walum E., 2005, Toxicol. Appl. Pharmacol., 207, S393, 10.1016/j.taap.2005.01.056 · DOI
- Fermini B., 2003, Nat. Rev. Drug Discovery, 2, 439, 10.1038/nrd1108 · DOI · Paper page
Cited by
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
Self-citationJohnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
REINVENT 2.0: An AI Tool for De Novo Drug Design
Blaschke, T., Arús-Pous, J., Chen, H., Margreitter, C., Tyrchan, C., Engkvist, O., Papadopoulos, K., & Patronov, A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00915 · Cited by 496
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
Metadata
- Authors
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-03-25
- Volume
- 1
- Issue
- 6
- Pages
- 435-449
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2016575780
- Cited by
- 1,063
- References
- 2
- FWCI
- 38.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties. https://app.cochat.ai/papers/10.1021/cn100008c
- The paper
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010). Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties. ACS Chemical Neuroscience. https://doi.org/10.1021/cn100008c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.